IL-1 Signal Inhibition in Alcoholic Hepatitis

Registry ID

EUCTR2017-003724-79

Source registry

EUCTR

Status

GB - no longer in EU/EEA

Phase

PHASE2

Sponsor

Imperial College London

Start date

2018-05-23

Last update

2026-08-16

Conditions

• Alcoholic Hepatitis

Summary

The objective is to explore the potential benefits of the IL-1β antibody, Canakinumab, in the treatment of alcoholic hepatitis

Locations

• , , UK

Related clinical trials

• Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH
• PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis
• Intra-Hepatic Microbiota in Alcoholic Hepatitis
• Utility of the Use of N-acetylcysteine Associated With Conventional Treatment in Patients With Severe Acute Alcoholic Hepatitis (Maddrey> 32)
• Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis
• HA35 Moderate Alcoholic Hepatitis (AH) Study

View on source registry